D. Boral Capital Reiterates Buy Rating for FibroBiologics (NASDAQ:FBLG)

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $16.00 price target on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of FibroBiologics in a research note on Tuesday, April 1st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, FibroBiologics currently has a consensus rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Stock Down 8.4%

Shares of FBLG stock opened at $0.93 on Thursday. The company has a market capitalization of $35.74 million, a price-to-earnings ratio of -4.45 and a beta of -0.25. FibroBiologics has a 12-month low of $0.76 and a 12-month high of $13.59. The firm has a fifty day moving average of $1.00 and a 200-day moving average of $1.69.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). On average, equities analysts expect that FibroBiologics will post -0.53 EPS for the current year.

Hedge Funds Weigh In On FibroBiologics

A number of institutional investors have recently added to or reduced their stakes in FBLG. Barclays PLC increased its position in FibroBiologics by 363.2% in the 3rd quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after acquiring an additional 31,331 shares during the period. Virtu Financial LLC bought a new position in shares of FibroBiologics during the fourth quarter valued at about $30,000. Jane Street Group LLC purchased a new stake in FibroBiologics during the third quarter worth about $37,000. Cerity Partners LLC increased its holdings in FibroBiologics by 49.9% during the fourth quarter. Cerity Partners LLC now owns 78,101 shares of the company’s stock worth $156,000 after buying an additional 26,001 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of FibroBiologics in the fourth quarter worth about $37,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.